US biotech firm Spectrum Pharmaceuticals (NasdaqGS: SPPI) has entered into a strategic partnership with the Canadian subsidiary of French privately-held drugmaker Servier for the marketing of several of its drug products.
As part of this partnership, Spectrum will grant the exclusive rights to develop and commercialize in Canada a franchise of four Spectrum hemato-oncology drugs: Zevalin (ibritumomab tiuxetan), Folotyn (pralatrexate), Beleodaq (belinostat) and Marqibo (vinCRIStine sulfate Liposome). Spectrum will receive $6 million in upfront payments, plus development milestone payments and royalties based on net product sales.
“We are pleased to announce this strategic partnership with Servier, a leading company in Canada,” said Rajesh Shrotriya, chairman and chief executive of Spectrum Pharmaceuticals.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze